Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study of Stereotactic Radiosurgery Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-line Chemotherapy

NCT05718466 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT05718466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05718466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study of Stereotactic Radiosurgery Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-line Chemotherapy
Lead sponsor
Henry Ford Health System
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2016
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or progressive glioblastoma